Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, S. | - |
dc.contributor.author | Son, M. | - |
dc.contributor.author | Park, C.-H. | - |
dc.contributor.author | Jang, J.T. | - |
dc.contributor.author | Son, K.H. | - |
dc.contributor.author | Byun, K. | - |
dc.date.available | 2020-09-14T01:35:58Z | - |
dc.date.created | 2020-08-10 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 1660-3397 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78208 | - |
dc.description.abstract | Hyperlipidemia induces vascular smooth muscle cell (VSMC) proliferation and phenotype switching from contractile to synthetic. This process is involved in arterial remodeling via the chemokine ligand 5 (CCL5)/chemokine receptor 5 (CCR5) pathway. Arterial remodeling is related to atherosclerosis or intimal hyperplasia. The purpose of this study was to evaluate whether pyrogallol-phloroglucinol-6,6-bieckol (PPB) from E. cava reduces VSMC proliferation and phenotype switching via the CCL5/CCR5 pathway. The CCL5/CCR5 expression, VSMC proliferation and phenotypic alterations were evaluated using a cell model of VSMC exposed in hyperlipidemia, and an animal model of mice fed a high-fat-diet (HFD). The expression of CCL5/CCR5 increased in both the cell and animal models of hyperlipidemia. Treatment with PPB decreased CCL5/CCR5 expression in both models. The expression of contractile markers of VSMCs, including alpha-smooth muscle actin (α-SMA), smooth muscle myosin heavy chain (SM-MHC), and smooth muscle protein 22 alpha (SM22α), were decreased by hyperlipidemia and restored after treatment with PPB. The silencing of CCR5 attenuated the effects of PPB treatment. VSMC proliferation and the intima-media thickness of the aortas, increased with HFD and decreased after treatment with PPB. The VSMC proliferation ratio and messenger ribonucleic acid (mRNA) expression of cell cycle regulatory factors increased in the in vitro model and were restored after treatment with PPB. PPB treatment reduced VSMC proliferation and phenotype switching induced by hyperlipidemia through inhibition of the CCL5/CCR5 pathway. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | Marine drugs | - |
dc.title | Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5 | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000564101200001 | - |
dc.identifier.doi | 10.3390/md18080393 | - |
dc.identifier.bibliographicCitation | Marine drugs, v.18, no.8 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85088851640 | - |
dc.citation.title | Marine drugs | - |
dc.citation.volume | 18 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Oh, S. | - |
dc.contributor.affiliatedAuthor | Son, M. | - |
dc.contributor.affiliatedAuthor | Park, C.-H. | - |
dc.contributor.affiliatedAuthor | Son, K.H. | - |
dc.contributor.affiliatedAuthor | Byun, K. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | chemokine receptor 5 | - |
dc.subject.keywordAuthor | Ecklonia cava | - |
dc.subject.keywordAuthor | pyrogallol-phloroglucinol-6,6′-bieckol | - |
dc.subject.keywordAuthor | vascular smooth muscle cell phenotype switching | - |
dc.subject.keywordAuthor | vascular smooth muscle cell proliferation | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.